Soligenix, Inc. (SNGX) financial statements (2021 and earlier)

Company profile

Business Address 29 EMMONS DRIVE
PRINCETON, NJ 08540
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments5989566
Cash and cash equivalents5989566
Receivables111121 
Prepaid expense1000000
Deferred costs0      
Income taxes receivable1
Other undisclosed current assets0     1
Total current assets:710910768
Noncurrent Assets
Property, plant and equipment0000000
Intangible assets, net (including goodwill)0000001
Intangible assets, net (excluding goodwill)0000001
Deposits noncurrent assets000    
Assets held-in-trust0      
Other noncurrent assets0      
Other undisclosed noncurrent assets00     
Total noncurrent assets:0000001
TOTAL ASSETS:8101010778
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities6433532
Accounts payable3222432
Accrued liabilities3211   
Employee-related liabilities0000000
Debt    0  
Derivative instruments and hedges, liabilities    248
Other undisclosed current liabilities0      
Total current liabilities:64337710
Noncurrent Liabilities
Other undisclosed noncurrent liabilities0      
Total noncurrent liabilities:0      
Total liabilities:64337710
Stockholders' equity
Stockholders' equity attributable to parent1667(0)(0)(2)
Common stock0000000
Additional paid in capital177172164158147139131
Accumulated other comprehensive loss(0)(0)     
Accumulated deficit(176)(166)(157)(150)(147)(139)(132)
Total stockholders' equity:1667(0)(0)(2)
TOTAL LIABILITIES AND EQUITY:8101010778

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Revenues55510973
Revenue, net510973
Cost of revenue(4)(5)(4)(8)(7)(5)(3)
Gross profit:1112221
Operating expenses(12)(10)(9)(8)(9)(12)(8)
Operating loss:(11)(9)(8)(6)(7)(11)(7)
Nonoperating income (expense)0002(1)3(4)
Investment income, nonoperating0002 3(4)
Interest and debt expense(0)      
Other undisclosed income from continuing operations before equity method investments, income taxes0      
Loss from continuing operations before income taxes:(10)(9)(8)(4)(8)(7)(11)
Income tax benefit1 01011
Net loss available to common stockholders, basic:(9)(9)(7)(3)(8)(7)(10)
Other undisclosed net loss available to common stockholders, diluted   (2) (3) 
Net loss available to common stockholders, diluted:(9)(9)(7)(5)(8)(10)(10)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net loss:(9)(9)(7)(3)(8)(7)(10)
Comprehensive loss:(9)(9)(7)(3)(8)(7)(10)
Other undisclosed comprehensive loss, net of tax, attributable to parent(0)(0)     
Comprehensive loss, net of tax, attributable to parent:(9)(9)(7)(3)(8)(7)(10)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: